Zusammenfassung
Diese Einschätzung wurde am 09.10.18 mit einem Endkurs von 2,98 € beendet. Mit einer Rendite von 10,37 % entwickelte sich die Einschätzung BUY ganz nach Plan. melinda hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| iCAD Inc | - | - | - | - |
| iShares Core DAX® | -0,92 % | -1,99 % | 13,40 % | 16,08 % |
| iShares Nasdaq 100 | 0,37 % | -0,87 % | 41,54 % | 46,94 % |
| iShares Nikkei 225® | 2,22 % | -5,19 % | 20,50 % | 4,64 % |
| iShares S&P 500 | -0,03 % | -0,92 % | 30,41 % | 42,42 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion iCAD Inc diskutieren
SecteurMatériel informatique Agenda 31/10 Publication de résultats
Provides Computer-Aided Detection solutions
iCAD, Inc. engages in the provision of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer.
It operates through the Cancer Detection and Cancer Therapy business segments.
The Cancer Detection segment includes image analysis and clinical decision support solutions for mammography, breast tomosynthesis, and computed tomography imaging.
The Cancer Therapy segment offers an isotope-free cancer treatment platform technology.
The company was founded in 1984 and is headquartered in Nashua, NH.
iCAD, Inc. engages in the provision of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer.
It operates through the Cancer Detection and Cancer Therapy business segments.
The Cancer Detection segment includes image analysis and clinical decision support solutions for mammography, breast tomosynthesis, and computed tomography imaging.
The Cancer Therapy segment offers an isotope-free cancer treatment platform technology.
The company was founded in 1984 and is headquartered in Nashua, NH.
Nombre d'employés : 119 personnes
(Zielkurs erreicht)